A Tribute to The Michael J. Fox Foundation for Parkinson’s Research and Shake It Up Australia Foundation

by EpicentRx | Jan 25, 2023 | Blog

A recent email from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to research partners included a quote from Michael J. Fox himself in which the actor, optimist, and recent Oscar Jean Hersholt Humanitarian Award winner, referred to Parkinson’s disease...

A pandemic waiting to happen: Acute radiation syndrome and the immediate need for nuclear countermeasures

by EpicentRx | Jan 23, 2023 | Media

How Did EpicentRx Become EpicentRx?

by EpicentRx | Jan 20, 2023 | Blog

¡Más que una Radio! The names of companies, especially biotech companies, are often non-intuitive, hard to pronounce and even harder to spell, sometimes on purpose, making it next to impossible to figure out the general focus of these companies let alone exactly what...

Eyeing untapped niche, EpicentRx makes case for cancer toxicity prevention drug

by EpicentRx | Jan 20, 2023 | Media

EpicentRx Announces Presentation for Phase 2 Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 vs. regorafenib in Third/Fourth Line Colorectal Cancer at the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

by EpicentRx | Jan 20, 2023 | 2023, Press Releases

Torrey Pines, Calif., January 20, 2023 – EpicentRx, Inc, a leading-edge, clinical-stage biopharmaceutical company that uses groundbreaking science to treat cancer and inflammatory-driven diseases, today announced data from a Phase 2 randomized clinical trial of...